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Introduction
Acute kidney injury (AKI) results from events such as renal isch-
emia, nephrotoxicity, and/or sepsis. AKI increases the risk of death 
in the intensive care unit (ICU), and mortality rates in this setting 
range between 15%–60% (1–3). Survival from AKI is dependent on 
recovery of renal function following injury, the success of which 
has been suggested to be dependent on the efficiency of adap-
tive repair processes (4, 5). Progression of chronic kidney disease 
(CKD) and end-stage kidney disease are recognized as possible 
outcomes for AKI patients, and it has been suggested that incom-
plete or maladaptive repair may predispose progression of CKD 
following AKI (4, 5).
Immune cell activity may contribute to renal injury or may 
enhance renal recovery. In the setting of renal ischemia reperfu-
sion (I/R) injury, renal CD4+ Th1 or Th17 cells are thought to exac-
erbate renal injury while T regulatory cells have been implicated 
in renal repair (6, 7). Following recovery from I/R injury in rats, 
subsequent exposure to high-salt diet was shown to hasten the 
development of interstitial fibrosis, inflammation, proteinuria, 
and hypertension. These parameters of CKD progression were 
significantly attenuated by immunosuppression with mycopheno-
late (8, 9), suggesting that lymphocyte activity also modulates the 
AKI-to-CKD transition.
Naive CD4+ cells differentiate into effector T helper cells in 
the ischemic milieu, where they are exposed to different antigens 
and proinflammatory cytokines. T helper cells secrete various cyto-
kines and are thought to orchestrate the adaptive immune response 
(6). Our group demonstrated that Th17 cells, which secrete the 
cytokine IL-17, are the prominent lymphocyte population found in 
rat kidney following I/R injury (10). These cells have been impli-
cated in a variety of autoimmune diseases such as asthma, psori-
asis, inflammatory bowel disease, and lupus erythematosus (11). 
There is a significant expansion of Th17 cells in kidney within 
the first 3 days of I/R injury in rats, whereas Th17 levels resolve to 
near sham-operated control values within 7 days as renal function 
recovers. However, subsequent exposure of rats to high-salt diet 
(4%) strongly reactivates Th17 cell expression in post-ischemic kid-
ney (10). This reactivation may contribute to CKD, since an IL-17R 
antagonist attenuated renal interstitial fibrosis and neutrophil infil-
tration in post I/R rats exposed to high-salt diet (12).
The basis for activation of Th17 cells in response to renal 
injury and exposure to high-salt diet remains to be elucidated. 
Th17 cell differentiation is dependent on the activity of the 
transcription factor RORγT, and inhibitors of this factor can 
alleviate the pathological activation of Th17 cells (13). Activa-
tion of these cells by high-salt diet has also been demonstrated 
in a mouse model of autoimmune encephalitis and associated 
with the activity of serum and glucocorticoid regulated kinase 
(SGK-1) and nuclear factor of activated T cells 5 (NFAT5) (14). 
Elevation of extracellular Na+ to 170 mM enhanced differenti-
ation from naive CD4+ cells to Th17 cells in vitro in a process 
dependent on SGK-1 (15).
We hypothesized that the store-operated calcium entry (SOCE) channel, Orai1, participates in the activation of Th17 cells and 
influences renal injury. In rats, following renal ischemia/reperfusion (I/R), there was a rapid and sustained influx of Orai1+ CD4 
T cells and IL-17 expression was restricted to Orai1+ cells. When kidney CD4+ cells of post–acute kidney injury (post-AKI) rats 
were stimulated with angiotensin II and elevated Na+ (10–7 M/170 mM) in vitro, there was an enhanced response in intracellular 
Ca2+ and IL-17 expression, which was blocked by SOCE inhibitors 2APB, YM58483/BTP2, or AnCoA4. In vivo, YM58483/BTP2 
(1 mg/kg) attenuated IL-17+ cell activation, inflammation, and severity of AKI following either I/R or intramuscular glycerol 
injection. Rats treated with high-salt diet (5–9 weeks after I/R) manifested progressive disease indicated by enhanced 
inflammation, fibrosis, and impaired renal function. These responses were significantly attenuated by YM58483/BTP2. In 
peripheral blood of critically ill patients, Orai1+ cells were significantly elevated by approximately 10-fold and Th17 cells were 
elevated by approximately 4-fold in AKI versus non-AKI patients. Further, in vitro stimulation of CD4+ cells from AKI patients 
increased IL-17, which was blocked by SOCE inhibitors. These data suggest that Orai1 SOCE is a potential therapeutic target in 
AKI and CKD progression.
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To investigate the potential that Orai1 participates in AKI, Orai1 
expression was measured in Th17 cells from kidneys of rats 2 days 
following sham or I/R injury (Study I). Orai1 was detected in Th17 
cells and the number of these cells was increased following I/R 
relative to sham (Figure 1A). When accounting for influx, the total 
number of CD4+/Orai1+ cells and the number of triple-positive 
CD4+/IL-17+/Orai1+ cells in kidney were markedly elevated by 
I/R injury (Figure 1, B and C). In CD4+ cells, Orai1 was associated 
with increased IL-17 signal (Figure 1D) and IL-17+ cells were found 
almost exclusively in Orai1+ cells in both sham and post-I/R groups 
(Figure 1E). Orai1 expression was also observed in CD8+, B cells, 
NK cells, and macrophages but the percentage of these popula-
tions was modest when compared with CD4+ cells (Supplemental 
Table 2; supplemental material available online with this article; 
https://doi.org/10.1172/JCI126108DS1). Orai1 has 2 homologs, 
referred to Orai2 and Orai3, which have been suggested to mod-
ulate lymphocyte responses (19, 20). However, neither Orai2 nor 
Orai3 was significantly affected by I/R and neither Orai2+ nor 
Oria3+ cells coexpressed IL-17 (Supplemental Figure 2).
Using an in vitro stimulation assay, we demonstrated that 
CD4+ T cells from post-ischemic kidney manifest enhanced 
expression of IL-17 in response to Ang II and elevated extracellular 
Na+ in vitro, while no response was observed from sham-operated 
control-derived CD4+ cells (12). The mechanisms mediating the 
enhanced IL-17 activation in CD4+ cells after AKI are not known. 
Previous studies have demonstrated that Orai1, the pore-forming 
subunit of Ca2+ release-activated Ca2+ channels (CRAC), is required 
for Th17 cell differentiation in vitro, due in part to NFAT activity 
(16, 17). Interestingly, Orai1 mutant mice or inhibitors of Orai1 
show impaired T cell receptor (TCR) activation and reduced IL-17 
production, and are resistant to autoimmune disorders (17). There-
fore, we tested the hypothesis that renal I/R enhances lymphocyte 
Orai1-mediated Ca2+ signaling that drives Th17 cell expression and, 
in turn, modulates AKI and AKI-to-CKD progression.
Results
Previous studies demonstrated that Th17 cells are rapidly induced 
following renal I/R and that IL-17 contributes to AKI (10, 18). 
Figure 1. Coexpression of Orai1 and IL-17 in CD4+ T cells following renal I/R. (A) Contour plot of renal lymphocytes stained with antibodies for CD4 and 
IL-17 to identify Th17 cells (left). Orai1 staining in gated Th17 cells of sham (middle) and 2 days after I/R (right). (B) The number of Orai1+/CD4+ cells in sham 
and post-I/R rat kidneys. (C) The number of Orai1+/CD4+/IL-17+ cells in sham and post-I/R rat kidneys. (D) Representative histogram of Orai1+ cells in kidney 
CD4+ fraction (left) 2 days after I/R, and the distribution of IL-17 expression as a function of Oria1 (right). (E) The percentage of IL-17+ cells as a function of 
Orai1 expression in CD4+ cells following sham surgery or 2 days after I/R. (F) Sustained expression of Orai1 in CD4+ cells following 7 days of recovery from 
I/R surgery is shown as a representative histogram (left); total number of Orai1+/CD4 cells (right). In B, C, E, and F, data are mean ± SE of 4–5 rats per 
group. *P < 0.05  for sham versus post-AKI by Student’s t test (B, C, F) and for sham versus I/R (E); †P < 0.05 in Orai1– versus Orai1+ cells, by 1-way ANOVA 
and Tukey’s post hoc test.
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1.23 %; P < 0.05). Stimulation with Ang II and elevated Na+ did 
not affect the percentage of CD44+ effector memory T cells, sug-
gesting this population is not responsive to stimulation that pro-
motes IL-17 expression (Supplemental Figure 3C).
To evaluate a potential role for Orai1 in the IL-17 response, 
AKI-primed CD4+ cells were stimulated with Ang II and ele-
vated Na+ in the presence or absence of different SOCE inhib-
itors. Both 2-ABP and YM58483/BPT2 completely blocked the 
increase of IL-17 mRNA as well as the increase in IL-17+ cells 
(Figure 2, B and C). In addition, AnCoA4, an inhibitor consid-
ered to be highly specific for Orai1 due to its binding to stromal 
interaction molecule 1 (STIM1), thereby inhibiting gating of the 
Orai1 channel (21), also completely blocked the induction of 
IL-17 mRNA and protein.
To further evaluate Orai1 activity in AKI-primed CD4+ cells, 
intracellular free Ca2+ responses were evaluated with the fluores-
cent indicator fura-2. Representative tracings of sham-operated 
and AKI-primed CD4+ cells are shown in (Figure 2D). When the 
superfusate was changed to a buffer containing Ang II and ele-
vated Na+, a rapid and sustained increase in cytosolic Ca2+ was 
observed in a significant percentage of AKI-primed lymphocytes 
when compared with lymphocytes derived from sham-operated 
controls (Figure 2, D and E). The addition of either AnCoA4 
Kidney Th17 levels return to sham-operated control values 
within approximately 7 days of I/R (10). Despite the reduction 
of Th17 cells, Orai1 expression was maintained in CD4+ cells 
7 days after I/R (Figure 1F). Post-AKI rat kidneys also demon-
strate a greater percentage of CD4+ cells expressing the IL-17 
transcription factor, RORγT (Supplemental Figure 3A). When 
placed in culture, these AKI-primed CD4+ cells (7 days after 
I/R), but not sham CD4+ cells, increase IL-17 mRNA expression 
following in vitro stimulation with Ang II and elevated Na+ (10–7 
M/170 mM) (Supplemental Figure 3B) (10). This treatment also 
significantly increases the percentage of IL-17–expressing cells 
from approximately 12% to approximately 49% as detected by 
FACS (Figure 2, A and B). This response specifically requires 
elevated Na+, since increasing osmolality to a similar degree 
with either mannitol or choline chloride does not induce IL-17 
mRNA in the presence of Ang II (Supplemental Figure 3B). The 
IL-17+ cells induced following treatment coexpress RORγT, sug-
gesting activation of a predominately Th17 phenotype (Supple-
mental Figure 3C).
Kidney-derived CD4+ cells were examined further for mark-
ers of effector memory T cells (CD44+/CD62L–) 7 days following 
I/R injury. There was an approximately 4-fold increase in such 
cells from post-I/R rats versus sham (1.85% ± 0.01 % vs 7.65% ± 
Figure 2. Orai1 activity contributes to IL-17 expression in CD4+ lymphocytes primed by renal ischemia/reperfusion injury. (A) Representative FACS show-
ing increased IL-17 expression in CD4+ cells from 7-day post-AKI rats following stimulation in vitro with 170 mM Na+ and Ang II versus control media. (B) Per-
centage of IL-17+ cells in CD4+ cells isolated 7 days after sham or AKI and stimulated in vitro. (C) IL-17 mRNA, expressed as 2–ΔΔCT of kidney-derived CD4+ cells, 
isolated 7 days after I/R surgery and stimulated in vitro. In B and C, control refers to AKI-primed CD4+ cells stimulated with 170 mM Na+ and Ang II (10–7 M), 
and SOCE inhibitors are included as labeled. (D) Fura-2 fluorescence imaging of intracellular Ca2+ in CD4+ lymphocytes in response to increased Na+ (170 mM) 
plus Ang II (10–7 M), as indicated in the timeline and expressed as the ratio of fluorescence using 340/380 nm excitation. Shown are representative tracings 
of CD4+ cells from kidney following sham surgery (black) or I/R injury (red), or from I/R injury with coincubation with AnCoA4 (blue). The inset illustrates rep-
resentative visual field of multiple fura-2–loaded cells. (E) Percentage of cells manifesting an increase in Ca2+ response relative to baseline following in vitro 
stimulation with increased Na/Ang II. Data are mean ± SE from 4–5 rats per group per assay; *P < 0.05 versus unstimulated cells (i.e., no Ang II and normal 
Na, data not shown, see Supplemental Figure 3); †P < 0.05 inhibitors versus stimulated post-AKI cells by 1-way ANOVA and Tukey’s post hoc test.
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(Study II). YM58483/BPT2 significantly 
attenuated the level of renal injury 24 hours 
after reperfusion as indicated by the level of 
plasma creatinine (Figure 3A) and mRNA 
expression of kidney injury marker-1 
(Kim-1) (Figure 3B). YM58483/2-BPT also 
attenuated the infiltration of total CD4+ T 
cells, B cells, and dendritic cells following 
I/R (Figure 3, C–F). Total IL-17–expressing 
cells were significantly reduced by approxi-
mately 78% in YM58483/BPT2-treated rats 
relative to vehicle (Figure 3G). This reduc-
tion of IL-17+ was primarily observed in 
the CD4+ population (Figure 3H), whereas 
YM58483/BPT2 did not significantly effect 
CD8+ cells or CD8+ IL-17+ cells (Figure 3, 
D and I). Also, YM58483/BPT2 did not 
significantly influence either Th1 (IFN-γ; 
Figure 3J) or Th2 (IL-4+; data not shown) 
cells after ischemia.
Orai1 is present in immune cells, but 
may also be present in other cell types such 
as vascular cells. We sought to determine 
if the effect of YM58483/BPT on renal 
injury was primarily due to its effects on 
Th17 activation. To address this, rats were 
subjected to bilateral renal I/R and treated 
with either YM58483/BPT2, the IL-17Rc 
receptor antagonist, or both. Consistent 
with our previous data, YM58483/BPT2 
treatment alone significantly reduced 
plasma creatinine as compared with vehi-
cle controls in post-ischemic rats; however, 
IL-17Rc+YM58483/BPT2 treatment did not 
have any additional effect (Table 1). Levels 
of kidney CD4+ and CD4+/IL-17+ cells were 
significantly reduced versus vehicle-treated 
rats by a similar degree in both YM58483/
BPT- and IL-17Rc–treated rats (Table 1). 
When rats were treated with a combina-
tion of YM58483/BPT and IL-17Rc, the 
reduction in renal injury was similar to 
that observed with either YM58483/BPT 
or IL-17Rc alone (Table 1). The lack of an 
additional effect of IL-17Rc suggests that 
the primary effect of YM58483/BPT is 
due to inhibition of Th17 cells in the early 
post-ischemic period.
To further explore whether SOCE 
affects Th17 differentiation and renal 
injury, YM58483/BPT2 was tested in a 
different model of AKI associated with 
rhabdomyolysis. Intramuscular injection 
of glycerol into water-deprived rats resulted in severe renal injury 
(Table 2). In this model, renal CD8+ cells, including CD8+/IL-17+ 
cells, appeared to be the predominant lymphocyte population, as 
opposed to the more prevalent CD4+ lymphocyte response follow-
or YM58483/BPT2 significantly attenuated the percentage of 
Ca2+-responding cells to levels similar to sham.
To evaluate if SOCE influences Th17 cells in AKI, rats were fed 
YM58483/BPT2 approximately 2 hours prior to 40 minutes of I/R 
Figure 3. YM58483 pretreatment attenuates renal ischemia reperfusion injury. (A) Assessment 
of renal function by plasma creatinine 24 hours after I/R in Sprague-Dawley rats pretreated with 
YM-58483 or vehicle. Values for sham rats were 0.4 ± 0.1 mg/dL and are not shown on graph. (B) 
Kim-1 mRNA levels from total kidney RNA 24 hours after sham or I/R are shown. ND, not detectable. 
Total kidney-derived CD4+ and CD8+ cells are shown in C and D, respectively; total B cells (RT1B+) and 
dendritic/macrophage cells (DC/Mᶲ; CD11b/c+) are shown in E and F, respectively. The total number 
of IL-17+, CD4+/IL-17+ and CD8+/IL-17+ cells are shown in G, H, and I respectively. CD4+/IFN-γ+ cells are 
shown in J. Data are mean ± SE; n = 11 rats/group in A and n = 7–8 rats in B–J. *P < 0.05 I/R vehicle  
versus sham; †P < 0.05 vehicle versus YM58483 by 1-way ANOVA and Tukey’s post hoc test.
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tiation in human AKI, peripheral blood samples were obtained 
from critically ill patients with and without AKI. Samples were 
collected within 24–48 hours of AKI diagnosis for AKI cases or 
within 24–48 hours of ICU admission for frequency-matched 
(age, sex, baseline eGFR) controls without AKI (Table 3). In iso-
lated blood mononuclear cells, the percentages of total IL-17+ 
cells and CD4+/IL-17+ cells were significantly higher in AKI 
patients versus non-AKI patients (Figure 5, A–C). Moreover, the 
percentage of Orai1+ cells was also prominently increased from 
approximately 3% in non-AKI patients to approximately 30% 
in patients with AKI. Similar to studies in rat kidney, Th17 cells 
were predominantly found within Orai1-expressing cells versus 
Orai1– cells (Figure 5, D–F).
We next examined whether AKI enhanced IL-17 responses 
in circulating human CD4 cells and if these responses depend on 
SOCE activity. Human CD4+ cells responded in vitro to elevated 
extracellular sodium by increasing IL-17 expression in samples 
from AKI patients, but not in those from patients without AKI 
(Figure 5G). In contrast to rat kidney CD4+ cells, human blood 
CD4+ cells responded to elevated extracellular Na+ alone and did 
not require the addition of Ang II. Importantly, the IL-17 response 
appeared dependent on SOCE activity, since both YM58483/
BPT2 and AnCoA4 inhibited this response (Figure 5G).
Discussion
In this study, we propose a novel regulatory pathway related to 
the activation of lymphocytes in the setting of acute and chronic 
kidney injury based on the role of intracellular calcium signaling 
and the differentiation of Th17 cells. Our studies demonstrate that 
the store-operated Ca2+ channel Orai1 is prominently induced in 
renal T cells in the setting of kidney injury. Moreover, blockade 
of this channel attenuated Th17 cell induction and renal damage 
in response to ischemia/reperfusion injury as well as subsequent 
exposure to high-salt diet. Thus, Orai1 may represent a therapeu-
tic target to attenuate AKI or immune-mediated renal fibrosis and 
hypertension, which may occur secondary to AKI.
Th17 cells were originally described as a distinct T helper 
subset that  secretes the cytokine IL-17 and is a major factor in 
autoimmune disorders. Th17 cells play an important role in host 
defense. However, in models of asthma, inflammatory bowel dis-
ease, psoriasis, or autoimmune encephalitis, Th17 cells aggravate 
inflammation by recruitment of other immune cells (such as neu-
trophils), which express the IL-17RA receptor (23). Th17 cells have 
ing I/R. Nevertheless, YM58483/BPT2 significantly attenuated 
the rise in serum creatinine as well as the total number of IL-17–
expressing cells (Table 2).
Exposure of rats to high-salt diet at 5 weeks following recov-
ery from I/R restimulates renal Th17 cell activity that is thought 
to contribute to CKD progression (10). The effect of SOCE on 
Th17 activation by high-salt diet following AKI was evaluated in 
rats subjected to unilateral renal I/R followed by contralateral 
nephrectomy and transition to high-salt diet (Study III). Post-AKI 
rats treated with vehicle during high-salt diet treatment man-
ifested a significant infiltration of kidney CD4+ and CD8+ cells 
and IL-17–expressing cells. YM58483/BPT2 treatment signifi-
cantly attenuated the increase in CD4+ and CD8+ cells and the 
increased expression of IL-17+ cells (Figure 4, A–D). YM58483/
BPT2 also significantly attenuated the increase in B cells and 
Mᶲ/dendritic cells in post-AKI rats fed high-salt diet (Figure 4, E 
and F). Creatinine clearance at the end of the study period (i.e., 
9 weeks after I/R) was significantly reduced in vehicle-treated 
I/R rats relative to sham-operated controls, but creatinine clear-
ance was not reduced in YM58483/BPT2-treated rats relative to 
sham (Figure 4G). Post-ischemic rats treated with vehicle also 
showed significant alterations in other parameters related to 
CKD, including urinary albumin excretion, the development of 
interstitial fibrosis, and the expression of Kim-1; these parame-
ters were all significantly attenuated in YM58483/BPT2-treated 
rats (Figure 4, H and I; and Supplemental Figure 4).
We previously demonstrated increased circulating Th17 cells 
in rat blood following I/R, suggesting that blood may be used as 
source of activated lymphocytes in the setting of AKI (22). To 
investigate the potential that SOCE influences Th17 differen-
Table 2. Effect of SOCE inhibitor YM58483 on glycerol-induced 
kidney injury and lymphocyte content 24 hours after injection
Glycerol+ Vehicle (n = 5) Glycerol+YM58434 (n = 5)
Serum creatinine, mg/dL 4.2 ± 0.3 3.3 ± 0.4A
CD4+, cells/g 234,294 ± 24,717 177,606 ± 282
CD8+, cells/g 552,129 ± 139,124 342,433 ± 76,011
Total IL-17+, cells/g 112,343 ± 19,217 60,109 ± 21,033A
CD4+/IL-17+, cells/g 34,972 ± 3108 20,622 ± 4191A
CD8+/IL-17+, cells/g 57,667 ± 1820 19,711 ± 6499A
Data are mean ± SE. AP < 0.05 by Student’s t test.
 
Table 1. Effect of SOCE inhibitor YM58483 and IL-17Rc on renal injury and renal lymphocyte content 24 hours following ischemia 
reperfusion
Sham (n = 3) I/R+Vehicle (n = 6) I/R+YM58483 (n = 5) I/R+IL-17Rc (n = 8) I/R+YM+IL-Rc (n = 8)
Serum creatinine, mg/dL 0.7 ± 0.1 5.1 ± 0.8A 3.7 ± 0.6B 3.96 ± 1.2 3.9 ± 1.0
CD4+, cells/g 19,590 ± 2812 118,964 ± 11,193A 26,156 ± 4365B 19,229 ± 3175B 18,636 ± 3140B
CD8+ cells, cells/g 2446 ± 295 31,237 ± 5362A 8410 ± 1386B 4356 ± 559B 4929 ± 974B
Total IL-17+, cells/g 4117 ± 671 17,887 ± 14,133A 9334 ± 4293B 8447 ± 1753B 8718 ± 1630B
CD4+/IL-17+, cells/g 1937 ± 540 8111 ± 3903A 2020 ± 731B 1567 ± 294B 1694 ± 262B
CD8+IL-17+, cells/g 30 ± 1.1 1647 ± 770A 127 ± 23B 251 ± 118B 281 ± 173B
Data are mean ± SE. AP < 0.05 I/R vehicle versus sham. BP < 0.05 versus vehicle by 1-way ANOVA and Tukey’s multiple comparison test.
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also received significant attention in the setting of renal inflam-
matory disorders, including anti–neutrophil cytoplasmic anti-
body–associated (ANCA-associated) vasculitis (24), crescentic 
glomerular nephritis (25), and nephrotic syndrome (26, 27). Fol-
lowing renal transplant, there is an increased prevalence of Th17 
cells in patients with chronic allograft nephropathy (28).
Th17 cells have recently been examined in the setting of 
AKI. Studies using Il17-null mice suggest that Th17 cells contrib-
ute to the severity of renal injury in response to I/R (29) or cis-
platin (18). Work from our group demonstrated a biphasic Th17 
response in rats, with an early transient phase of expression 
peaking between 1–3 days following injury and the second peak 
induced when rats are provided high-salt diet. Th17 cells were 
the predominant lymphocyte population activated by high-salt 
diet, whereas no significant effect was observed on Th1 or Th2 
cells (12). The exposure to high-salt diet exacerbates inflam-
mation, fibrosis, and hypertension, and can be attenuated by 
mycophenolate or an IL-17 antagonist (8, 12). Therefore, the 
mechanisms mediating IL-17 expression in response to I/R and 
high-salt intake are of interest. An in vitro model using CD4+ 
cells from kidneys 7 days after I/R revealed that stimulation by 
Ang II and elevated extra-
cellular sodium increased 
IL-17 expression while hav-
ing no effect on Th1 or Th2 
responses (12). This prim-
ing of CD4+ cells by AKI 
provided an opportunity 
to investigate altered lym-
phocyte signaling leading 
to Th17 differentiation in 
response to renal injury, 
and it was the basis of the 
current study.
Kleinewietfeld et al. 
investigated the potential 
mechanism by which Na+ 
may directly influence Th17 
cell differentiation. These 
authors demonstrated that 
naive T cells, when cultured 
for 4 days with TGF-β and 
IL-6, differentiate into Th17 
cells. This response was 
potentiated by elevating the 
concentration of Na+ in the 
culture media. In addition, 
the response was abrogated 
by inhibition of p38/MAPK, 
NFAT5, and SGK-1. It was 
suggested that the increase 
in Na+ concentration by up to 
an additional 40 mM might 
be observed in skin under 
high-salt diet conditions and 
potentially influence T cell 
function. Indeed, Th17 induc-
tion and severity of autoimmune encephalopathy was enhanced 
when mice were placed on a high-salt diet (14).
TCR stimulation invokes an increase in intracellular Ca2+ 
via Ca2+ release–activated Ca2+ channels (CRAC). The result of 
this activity is thought to be calcineurin-mediated dephosphor-
ylation of NFAT, which translocates to the nucleus and activates 
transcriptional programs. Genome-wide RNAi screens helped to 
identify Orai1 as the pore-forming subunit of CRAC channels (16, 
30). Activation of Orai1 is mediated by the activity of STIM1, an 
endoplasmic reticulum (ER) membrane spanning protein, which 
senses Ca2+ depletion from the ER secondary to TCR stimulation. 
Interaction between STIM1 and Orai1 increases CRAC activity 
and results in sustained increases in intracellular Ca2+ (31). Muta-
tions in either ORAI1 or STIM1 result in a severe combined immu-
nodeficiency (SCID) phenotype (32). For Th17 cell differentiation, 
TCR stimulation in combination with various other cytokines 
represents an important driver of differentiation, which is consid-
ered more inflammatory than Th1 or Th2 phenotypes. Interesting-
ly, chemical library screening recently identified putative Orai1 
inhibitors, which showed greater selectivity in abrogating Th17 
differentiation versus Th1 or Th2 differentiation. Moreover, Orai1 
Table 3. Characteristics of patients according to AKI status
Total AKI Controls P
Number of patients 17 9 8
Demographics
 Age, years, mean ± SD 63.9 ± 10.9 63.8 ± 12.0 64.1 ± 10.4 0.063
 Male, n (%) 11 7 (77.8) 4 (50.0) 0.232
 White race, n (%) 15 9 (100.0) 6 (75.0) 0.110
 BMI, kg/m2, median [IQ1–IQ3] 26.0 [23.1–34.4] 33.9 [24.9–35.9] 25.9 [24.5–28.9] 0.481
Baseline kidney function
 eGFR, mL/min/1.73 m2, median [IQ1–IQ3] 89.0 [74.2–106.1] 83.2 [75.4–89.0] 100.7 [91.1–105.1] 0.481
 SCr, mg/dL, median [IQ1-IQ3] 0.7 [0.6–0.9] 0.9 [0.7–1.0] 0.7 [0.6–0.8] 0.093
Comorbidity
 Charlson comorbidity score, median [IQ1–IQ3] 3.0 [2.0–4.5] 3.0 [2.0–5.0] 3.0 [2.8–3.3] 0.888
 Diabetes, n (%) 8 6 (66.7) 2 (25.0) 0.086
 Hypertension, n (%) 14 7 (77.8) 7 (87.5) 0.600
 Congestive heart failure, n (%) 2 1 (11.1) 1 (12.5) 0.929
 COPD, n (%) 6 2 (22.2) 4 (50.0) 0.232
 Liver disease, n (%) 2 1 (11.1) 1 (12.5) 0.929
 Anemia, n (%) 7 3 (33.3) 4 (50.0) 0.486
 Cancer, n (%) 6 3 (33.3) 3 (37.5) 0.858
AKI characteristics
 Peak SCr, mg/dL, median [IQ1–IQ3] 2.9 [2.5–3.7] —
 KDIGO stage of AKI
  Stage 2, n (%) 3 (33.3) — 3 (33.3)
  Stage 3, n (%) 6 (66.7) — 6 (66.7)
Critical illness parameters
CFB 72 hours, L, median [IQ1–IQ3] 3.0 [0.8–4.3] 3.7 [3.0–4.8] 2.1 [0.8–3.0] 0.139
CFB ICU stay, L, median [IQ1–IQ3] 8.3 [2.7–25.6] 14.7 [6.4–35.4] 3.6 [3.1–6.3] 0.268
Pressor or inotrope, n (%) 8 8 (88.9) 0 (0.0) <0.001
Mechanical ventilation, n (%) 12 8 (88.9) 4 (50.0) 0.079
APACHE II score, median [IQ1–IQ3] 20.0 [14.5–26.0] 26.0 [21.0–32.0] 14.5 [12.0–17.3] <0.001
SOFA score, median [IQ1–IQ3] 7.0 [3.5–10.0] 10.0 [8.0–11.0] 3.5 [2.8–6.3] 0.002
Comparisons were done using Fisher’s exact test for categorical variables and Mann-Whitney U test for continuous 
variables.
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inhibition reduced the nuclear accumulation of NFAT and RORγT, 
critical transcriptional regulators of Th17 differentiation (16).
Data from the current study provide compelling evidence for an 
essential role of Orai1 in the differentiation of Th17 cells following 
renal I/R. IL-17–expressing CD4+ cells are rapidly expanded follow-
ing renal injury, and using FACS analysis we show that Orai1 expres-
sion is also prominent in kidney CD4+ cells following renal injury. 
Measurements from circulating blood of critically ill patients with 
AKI also demonstrated a profound enhancement of Ora1+ IL-17+ 
cells, indicating that this pathway is activated in human AKI.
Importantly, IL-17 expression was almost exclusive to cells 
expressing Orai1, and was essentially absent in Oria1– cells. Pub-
lished reports suggest that Orai1 mutations result in impaired 
production of Th17 cells. The data from the current study indicate 
that Orai1 is persistently expressed following the resolution of AKI 
(7 days after I/R). Given that the reexpression of IL-17 following 
Figure 4. YM58483 attenuates 
inflammation and progressive renal 
damage following I/R and exposure 
to high-salt diet. Shown are levels 
of renal CD4+ (A), CD8+ T cells (B), 
IL-17+ expressing cells (C), and CD4+/
IL-17+ cells (D). Levels of B cells (E) 
and dendritic cells/Mᶲ (F) are shown. 
(G) Creatinine clearance from 24-hour 
urine collections at day 62–63 and (H) 
urinary albumin/creatinine ratio. (I) 
Representative picrosirius red–stained 
sections through renal outer medulla 
from sham, I/R vehicle, or I/R plus 
YM58483-treated rats. (J) Quantifica-
tion of stained area. Data are mean 
± SE; n = 5–6 rats/group. *P < 0.05 
I/R vehicle vs sham; †P < 0.05 vehicle 
versus YM58483 by 1-way ANOVA and 
Tukey’s post hoc test.
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agents are in use to target this pathway in diseases such as 
psoriasis (33). IL-17 could also represent a target for both 
acute and chronic kidney disease since both have been 
shown to be ameliorated by IL-17 blockade or Il17 gene 
knockout strategies (9, 18). Similarly, we confirmed that a 
SOCE antagonist showed a significant degree of protection 
using a standard model of AKI in rats induced by bilateral 
renal I/R. We also extended this observation to a model 
of AKI secondary to rhabdomyolysis. The protection was 
associated with a clear reduction in the genesis of Th17 
cells in response to injury. However, since Orai1 may be 
expressed in endothelial cells or smooth muscle cells (34), 
we cannot exclude the possibility that the effects observed 
may be independent of IL-17 production. Nevertheless, in 
the current study, IL-17Rc blockade provided no additional 
protection over YM58483/BPT2 alone, suggesting that the 
primary activity of Orai1 in the early post-I/R period is to 
promote Th17 activation.
The transition from acute to chronic kidney disease 
has been the subject of significant research, and maladap-
tive repair responses predispose CKD progression (4). 
Since immune suppression strongly attenuates the AKI 
to CKD transition, persistent inflammation in the kid-
ney in response to AKI represents a potential maladaptive 
response. It is therefore noteworthy that Orai1 expression 
remains persistently elevated in CD4+ cells despite the 
recovery of kidney function and the decline in IL-17 expres-
sion. The degree and duration of sustained Orai1 expres-
sion following recovery from AKI remains unclear, but it is 
worth noting that reactivation of Th17 cells by high-salt diet 
was attenuated by SOCE inhibition 35–63 days after injury. 
Whether Orai1 persists in activated T cells, memory T cells, 
or other leukocyte populations that secrete IL-17 remains 
to be determined. Our studies demonstrated an increase in 
effector memory T cells 7 days after I/R. This population was not 
affected by in vitro stimulation, so it is not yet clear whether this 
population contributes directly to the IL-17 response after injury. 
Nevertheless, we suggest that sustained Orai1 expression may 
represent the basis for susceptibility to reactivation of Th17 cells 
in vitro stimulation is inhibited by SOCE antagonist, the results 
suggest that Orai1-mediated SOCE channel is required for Th17 
differentiation following I/R.
The potential ability to target IL-17 has already shown prom-
ise in the setting of autoimmune disease, and several therapeutic 
Figure 5. Elevated Th17 and Orai1 expression and effect of SOCE 
on IL-17 responses in CD4+ blood lymphocytes in critically ill 
patients with or without AKI. (A) Representative FACS analysis of 
total peripheral blood cells in non-AKI (left, n = 8) vs AKI patients 
(right, n = 9) demonstrating the increase in CD4+ IL-17+–expressing 
cells. Quantification of the percentages of total IL-17+ cells (B) and 
CD4+/IL-17+ cells (C) in AKI versus non-AKI patients are shown. 
Representative dot plots showing (D) an increase in Orai-1+ cells in 
AKI patients as compared with non-AKI patients and (E) the per-
centage of Orai-1+ cells in AKI vs non-AKI patients. (F) Percentage 
of CD4+/IL-17+ cells gated on Orai1+ and Orai1– fractions (arrows). (G) 
IL-17 response to stimulation with elevated sodium (170 mM) and 
Ang II is shown for CD4+ cells isolated from AKI (n = 5) or non-AKI 
(n = 5) patients. Data are expressed as mean ± SE. *P < 0.05 by 
Student’s t test in AKI versus non-AKI patients (B–D), in Orai1+ 
versus Orai1– cells (F),  or versus unstimulated (i.e., 140 mM and 
no Ang II) (G). †P < 0.05 inhibitors versus stimulated using 1-way 
ANOVA and Tukey’s post hoc test.
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ing, but were subjected to unilateral nephrectomy. Simultaneous with 
exposure to high-salt diet, rats were randomly assigned to vehicle or 
YM58483 treatment (1 mg • kg−1 • day−1; p.o.). At the end of all stud-
ies, rats were deeply anesthetized with 50–100 mg/kg pentobarbital 
(Fatal Plus, Vortech) and kidneys harvested for analysis.
Human studies. We designed a prospective case-control study to 
examine peripheral blood from AKI patients (n = 9) and matched con-
trols without AKI (n = 8) admitted to the ICU at the University of Ken-
tucky Hospital. AKI was defined by KDIGO criteria (42) using both 
serum creatinine (SCr) and urine output data. Only patients with AKI 
stage 2 or greater were included in the study as cases. Controls were 
frequency-matched by age (10-year intervals), sex, and 2-category 
baseline estimated glomerular filtration rate (eGFR, calculated using 
CKD EPI equation, ≥90 and 60–89 mL/min/1.73 m2). Baseline SCr 
was defined as the most recent SCr within the 6-month period before 
ICU admission. Inclusion criteria were as follows: adults ≥18 years of 
age, admission to the ICU, and baseline eGFR ≥60 mL/min/1.73 m2. 
Exclusion criteria consisted of prior kidney or any other solid organ 
transplant, end-stage kidney disease, evidence of AKI before ICU 
admission, or the presence of uroepithelial tumors.
Single-timepoint peripheral whole blood samples were obtained 
24–48 hours after AKI diagnosis (cases) or ICU admission (controls). 
Standardized techniques for blood collection, transport, and storage 
were employed.
Measurements of renal function. To measure creatinine, tail blood 
was collected in heparin-containing tubes and centrifuged to collect 
plasma. Plasma creatinine was measured using a Pointe Scientific 
Analyzer and Creatinine Assay reagents using methods outlined by 
the manufacturer. Urine was collected for 24 hours by placing rats in 
metabolic cages, and urine volume was determined gravimetrically. 
Urine creatinine was measured using a colorimetric assay adopted for 
microplate readers, as previously described (43). Creatinine clearance 
was measured using UCr*V/PCr.
Renal histology, immunohistochemistry, and RNA expression. At the 
time of tissue harvest, kidneys were bisected and one half was fixed by 
immersion in 10% formalin, embedded in paraffin, and 5-μm sections 
stained with Picrosirus red to assess fibrosis. For quantitative analysis, 
5 random images of renal outer medulla were obtained using Leica 
DMLB (Scientific Instruments) microscope with a ×20 objective. The 
percent area of Picrosirus red stain was scored in a blinded fashion 
with Image J (NIH) using procedures described previously (10).
Total RNA was obtained from kidney using Trizol and the Zymogen 
RNA extraction kit and cDNA was prepared using MMLV enzyme (Invi-
trogen). Quantitative real-time PCR (qPCR) using gene-specific primers 
was performed using ABI 7500 (Applied Biosystems). mRNA values 
were calculated using 2–ΔΔCt. Specific primers sequences for IL-6 (catalog 
Rn01410330_m1), Kim-1 (catalog Rn00597703_m1), and IL-17 (catalog 
Rn01757168_m1) were purchased from Thermo Fisher Scientific.
Rat CD4+ isolation and FACS analysis. Freshly harvested kidneys 
were minced and digested in liberase (2 μg/mL; Roche) for 15 minutes 
at 37°C using Gentle MACs (Miltenyi). The digested tissue was filtered 
through a 100-μm mesh and washed with RPMI containing 10% fetal 
bovine serum (Invitrogen). Mononuclear cells were isolated using 
Percol (MilliporeSigma) density gradient centrifugation.
All antibodies, their sources, and concentrations used are listed in 
Supplemental Table 1. To evaluate protein expression of IL-17 or Orai1, 
Orai2, or Orai3, cells were restimulated with PMA and ionomycin for 
and therefore represents an important link predisposing to salt- 
sensitive CKD progression following AKI.
In addition to providing a potential link between AKI and CKD, 
there is also clear evidence that CKD predisposes to AKI (35). It 
could be suggested that sustained expression of Orai1 in CKD may 
enhance sensitivity to AKI by promoting a greater inflammatory 
response to a given insult. It is also reasonable to suggest that 
increased Orai1 expression enhances the IL-17 response to other 
inputs. For example, in the current study, IL-17 expression was 
elevated in response to Ang II and elevated Na+ in vitro and was 
dependent on SOCE activity. Recent studies have shown that Ang 
II–dependent hypertension is, in part, dependent on IL-17 activ-
ity (36, 37); whether Orai1 modulates Ang II–dependent Th17 
responses in these models remains to be determined.
Taken together, the results from the current study suggest that 
Orai1 could be considered a novel pathway to target inflammatory 
renal disease associated with the Th17 phenotype. Novel inhibi-
tors targeting this pathway are currently in development (38) and 
could represent therapies for inflammatory diseases associated 
with Th17 cells, including autoimmune disease as well as AKI, 
CKD, and salt-sensitive hypertension.
Methods
Animal study protocols. All studies used male Sprague-Dawley rats (250–
300 g) that were purchased from Envigo. Rats were anesthetized with a 
cocktail of ketamine (100 mg/kg, KetoVed, Vedco Inc) and xylazine (50 
mg/kg, AnaSed, Lloyd Inc). Rats were placed on a heated surgical table 
to maintain body temperature. A midline incision and either unilateral 
(left) or bilateral renal ischemia (as indicated in Results) was induced by 
applying micro-aneurism clamps on the renal pedicles for a period of 40 
minutes. Reestablishment of perfusion was verified by visual examina-
tion following removal of the clamps. Rats were provided post-operative 
analgesia using buprenorphine-SR (1 mg/kg).
Rats were allowed to recover for various periods of time as 
described in Results. In Study I, lymphocytes were studied in vitro after 
recovery for either 2 or 7 days following I/R or sham surgery for evalu-
ation of function in vitro or for FACS analysis. In Study II, the effect of 
SOCE on kidney injury was studied with the inhibitor YM58483/BPT2 
(N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- 
1,2,3-thiadiazole-5-carboxamide; Tocris/Bio-Techne). Rats were 
pretreated p.o. 2–3 hours prior to surgery with YM58483.BPT2 
(1 mg • kg−1) in sugar-free chocolate pudding, following dilution in 
100% EtOH, at a dose previously shown to affect T cell activation in 
rats (39). In some experiments, rats were also treated with the IL-17Rc 
(150 ng/day i.p.; R&D Systems). In addition, one experiment utilized 
a model of rhabdomyolysis, induced by injection of 50% glycerol (10 
mL/kg) into the hindlimb muscle of rats following 16 hours of water 
restriction as previously described (40).
Study III was designed to investigate SOCE on progression of 
CKD induced by high-salt diet following recovery from I/R injury 
using a model of AKI-to-CKD described previously (41). Rats accli-
mated to a standard diet (AIN 76A, Dyets) containing 0.4% NaCl were 
subjected to left unilateral I/R or sham surgery and allowed to recover 
for approximately 5 weeks. Rats were then subjected to right unilat-
eral nephrectomy and subsequently exposed to elevated dietary Na+ 
(AIN76A plus 4% NaCl) for an additional 4 weeks (Supplemental Fig-
ure 4). Sham-control rats were not subjected to renal pedicle clamp-
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Statistics. All data are expressed as mean ± SE or SD or median 
[IQ1-IQ3]. For experimental data, differences in means were estab-
lished by 1-tailed Student’s t test or 1-way ANOVA with Tukey’s mul-
tiple comparison test as indicated in the figure legends. For clinical 
data, comparisons were done using Fisher’s exact test for categorical 
variables and Mann-Whitney U test for continuous variables. Analysis 
was done with the aid of Graph Pad Prism software or SAS 9.4 (SAS 
Institute). P<0.05 was considered significant.
Study approval. Rats were maintained in accordance with the pol-
icies of the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. All studies were approved by IACUC at Indiana 
University School of Medicine, Indianapolis, IN. For human studies, 
the protocol was approved by the IRB of the University of Kentucky, 
Lexington, KY. Written, informed consent was obtained for all study 
participants.
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6 hours in the presence of monensin (Golgistop, 1 μg/mL; BD Biosci-
ences) permeabilized with saponin (10%) and stained with relevant 
antibody. Cells were scanned using flow cytometry (FACSCalibur, BD 
Biosciences) and scans were analyzed using Flowjo software (Tree 
Star). Lymphocyte gating strategy was described previously (10) and 
a representative example of the gating strategy used in these studies is 
shown in Supplemental Figure 1.
Functional T cell analysis (rat). CD4+ T cells were isolated using 
the MACS Pan-T cell microbead separation kit (Miltenyi). T cells were 
stimulated with plate bound anti-CD3 (precoated with 2 μg/mL) and 
soluble anti-CD28 (1 μg/mL). Cells (2.5 × 105 in 0.25 mL) were incu-
bated 12–14 hours at 37°C in RPMI medium supplemented with 10% 
FBS (Invitrogen) in a 48-well plate. Cells were challenged with Ang II 
(MilliporeSigma, 10–7 M), raising the extracellular Na+ from 140 mM to 
170 mM using a 1M NaCl solution. Calcium channel inhibitors 2ABP 
(10 μM, MilliporeSigma), AnCoA4 (10 μM, Millipore), and YM58483/
BTP2 (10 μM) were included to evaluate effects on IL-17.
To assess Ca2+ responses, fura2 imaging was performed similar 
to methods previously described (44). Briefly, isolated CD4+ T cells 
were loaded with fura-2AM (2.5 μM, MilliporeSigma) for 45 minutes, 
washed, placed on poly-lysine (MilliporeSigma) coated coverslips, and 
placed in a superfusion chamber with physiological salt solution (PSS) 
containing 2 mM Ca2+. The chamber was mounted on an inverted 
epifluorescence microscope and signal measured with alternating 
excitation at 340 nm and 380 nm and emission at 510 nm using the 
InCa2+-imaging system (Intracellular Imaging Systems). Data were 
acquired at 1.5 Hz and representative tracings were smoothed to the 
10 nearest neighbor points using GraphPad Prism. For analysis, an 
increase in signal intensity of more than 1 standard deviation from 
baseline was considered a positive response. Frequency of respond-
ing cells was determined from an average 53 ± 19 cells for each ani-
mal. Cells that did not respond to the Ca2+ ionophore ionomycin 
(1 μM) at the conclusion of the study were excluded from analysis.
Human CD4+ isolation and FACS analysis. Fresh blood cells from 
patients were washed with PBS twice and stimulated with PMA, Iono, 
and monensin for 4–6 hours. Cells were stained for antibodies against 
IL-17, CD4+, and Orai-1 (Supplemental Table 2). The samples were ini-
tially blinded and diagnosis (AKI or non AKI) revealed after measure-
ments of all samples were completed.
For in vitro stimulation of human blood cells, primary T cells were 
isolated from fresh blood using Straight whole blood CD4 kit from 
Miltenyi Biotech according to manufactures` protocol. CD4+T cells 
were plated at a density of 1 × 106 cells/mL in RPMI medium supple-
mented with FBS. Cells were stimulated with human anti-CD3/CD28 
dynabeads (Gibco; catalog 11161D) along with labeled treatment over-
night (~12 hours). T cells were harvested and incubated with monensin 
for 6 hours, prior to staining for IL-17 (Supplemental Table 2).
 1. Basile DP, Anderson MD, Sutton TA. Pathophys-
iology of acute kidney injury. Compr Physiol. 
2012;2(2):1303–1353.
 2. Chertow GM, Burdick E, Honour M, Bonventre 
JV, Bates DW. Acute kidney injury, mortality, 
length of stay, and costs in hospitalized patients.  
J Am Soc Nephrol. 2005;16(11):3365–3370.
 3. Singbartl K, Kellum JA. AKI in the ICU: defini-
tion, epidemiology, risk stratification, and  
outcomes. Kidney Int. 2012;81(9):819–825.
 4. Basile DP, et al. Progression after AKI: Under-
standing maladaptive repair processes to predict 
and identify therapeutic treatments. J Am Soc 
Nephrol. 2016;27(3):687–697.
 5. Chawla LS, Eggers PW, Star RA, Kimmel PL. 
Acute kidney injury and chronic kidney disease 
as interconnected syndromes. N Engl J Med. 
2014;371(1):58–66.
 6. Jang HR, Rabb H. Immune cells in experi-
mental acute kidney injury. Nat Rev Nephrol. 
2015;11(2):88–101.
 7. Kinsey GR, Sharma R, Okusa MD. Reg-
ulatory T cells in AKI. J Am Soc Nephrol. 
2013;24(11):1720–1726.
 8. Pechman K, Basile DP, Lund H, Mattson DL. 
Immune suppression blocks sodium sensitive 
hypertension following recovery from acute 
renal failure. Am J Physiol Regulatory Integrative. 
2008;294(4):R1234–R1239.
 9. Mehrotra P, Collett JA, McKinney S, Stevens J, 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
4 9 6 1jci.org   Volume 129   Number 11   November 2019
Ivancic CM, Basile DP. IL-17 mediates neutrophil 
infiltration and renal fibrosis following recovery 
from ischemia reperfusion:compensatory role of 
natural killer cells in athymic rats. Am J Physiol 
Renal Physiol. 2017;312 (3):F385–FF97.
 10. Mehrotra P, Patel JB, Ivancic CM, Collett JA, Basile 
DP. Th-17 cell activation in response to high salt 
following acute kidney injury is associated with 
progressive fibrosis and attenuated by AT-1R 
antagonism. Kidney Int. 2015;88(4):776–784.
 11. Yang J, Sundrud MS, Skepner J, Yamagata T.  
Targeting Th17 cells in autoimmune diseases. 
Trends Pharmacol Sci. 2014;35(10):493–500.
 12. Mehrotra P, Collett JA, McKinney SD, Stevens J, 
Ivancic CM, Basile DP. IL-17 mediates neutrophil 
infiltration and renal fibrosis following recovery 
from ischemia reperfusion: compensatory role 
of natural killer cells in athymic rats. Am J Physiol 
Renal Physiol. 2017;312(3):F385–F397.
 13. Guendisch U, et al. Pharmacological inhibi-
tion of RORγt suppresses the Th17 pathway 
and alleviates arthritis in vivo. PLoS One. 
2017;12(11):e0188391.
 14. Kleinewietfeld M, et al. Sodium chloride drives 
autoimmune disease by the induction of pathogenic 
TH17 cells. Nature. 2013;496(7446):518–522.
 15. Wu C, et al. Induction of pathogenic TH17 cells 
by inducible salt-sensing kinase SGK1. Nature. 
2013;496(7446):513–517.
 16. Kim KD, et al. Calcium signaling via Orai1 is 
essential for induction of the nuclear orphan 
receptor pathway to drive Th17 differentiation.  
J Immunol. 2014;192(1):110–122.
 17. Feske S. Calcium signalling in lymphocyte 
activation and disease. Nat Rev Immunol. 
2007;7(9):690–702.
 18. Chan AJ, et al. Innate IL-17A-producing leuko-
cytes promote acute kidney injury via inflam-
masome and Toll-like receptor activation.  
Am J Pathol. 2014;184(5):1411–1418.
 19. Vaeth M, et al. ORAI2 modulates store-operated 
calcium entry and T cell-mediated immunity. 
Nat Commun. 2017;8:14714.
 20. Motiani RK, Stolwijk JA, Newton RL, Zhang X, 
Trebak M. Emerging roles of Orai3 in pathophys-
iology. Channels (Austin). 2013;7(5):392–401.
 21. Sadaghiani AM, et al. Identification of Orai1 
channel inhibitors by using minimal functional 
domains to screen small molecule microarrays. 
Chem Biol. 2014;21(10):1278–1292.
 22. Mehrotra P, Collett JA, Gunst SJ, Basile DP. 
Th17 cells contribute to pulmonary fibrosis and 
inflammation during chronic kidney disease pro-
gression after acute ischemia. Am J Physiol Regul 
Integr Comp Physiol. 2018;314(2):R265–R273.
 23. Monin L, Gaffen SL. Interleukin 17 family cyto-
kines: signaling mechanisms, biological activ-
ities, and therapeutic implications. Cold Spring 
Harb Perspect Biol. 2018;10(4):a028522.
 24. Nogueira E, et al. Serum IL-17 and IL-23 levels 
and autoantigen-specific Th17 cells are elevated 
in patients with ANCA-associated vasculitis. 
Nephrol Dial Transplant. 2010;25(7):2209–2217.
 25. Paust HJ, et al. Chemokines play a critical role in 
the cross-regulation of Th1 and Th17 immune 
responses in murine crescentic glomerulonephri-
tis. Kidney Int. 2012;82(1):72–83.
 26. Liu LL, et al. Th17/Treg imbalance in adult 
patients with minimal change nephrotic syn-
drome. Clin Immunol. 2011;139(3):314–320.
 27. Kitching AR, Holdsworth SR. The emergence of 
TH17 cells as effectors of renal injury. J Am Soc 
Nephrol. 2011;22(2):235–238.
 28. Chung BH, Kim KW, Kim BM, Doh KC, Cho ML, 
Yang CW. Increase of Th17 cell phenotype in  
kidney transplant recipients with chronic allograft 
dysfunction. PLoS One. 2015;10(12):e0145258.
 29. Guo L, Lee HH, Noriega ML, Paust HJ, Zahner 
G, Thaiss F. Lymphocyte-specific deletion 
of IKK2 or NEMO mediates an increase in 
intrarenal Th17 cells and accelerates renal 
damage in an ischemia-reperfusion injury 
mouse model. Am J Physiol Renal Physiol. 
2016;311(5):F1005–F1014.
 30. Feske S, et al. A mutation in Orai1 causes immune 
deficiency by abrogating CRAC channel func-
tion. Nature. 2006;441(7090):179–185.
 31. Derler I, Jardin I, Romanin C. Molecular mecha-
nisms of STIM/Orai communication. Am J Physi-
ol, Cell Physiol. 2016;310(8):C643–C662.
 32. Feske S, Picard C, Fischer A. Immunodeficiency 
due to mutations in ORAI1 and STIM1. Clin 
Immunol. 2010;135(2):169–182.
 33. Chiricozzi A, Krueger JG. IL-17 targeted ther-
apies for psoriasis. Expert Opin Investig Drugs. 
2013;22(8):993–1005.
 34. Xu N, Cioffi DL, Alexeyev M, Rich TC, Stevens T. 
Sodium entry through endothelial store-operated 
calcium entry channels: regulation by Orai1. Am J 
Physiol, Cell Physiol. 2015;308(4):C277–C288.
 35. He L, et al. AKI on CKD: heightened injury, sup-
pressed repair, and the underlying mechanisms. 
Kidney Int. 2017;92(5):1071–1083.
 36. Wade B, Petrova G, Mattson DL. Role of immune 
factors in angiotensin II-induced hypertension  
and renal damage in Dahl salt-sensitive 
rats. Am J Physiol Regul Integr Comp Physiol. 
2018;314(3):R323–R333.
 37. Madhur MS, et al. Interleukin 17 promotes angio-
tensin II-induced hypertension and vascular 
dysfunction. Hypertension. 2010;55(2):500–507.
 38. Tian C, Du L, Zhou Y, Li M. Store-operated CRAC 
channel inhibitors: opportunities and challenges. 
Future Med Chem. 2016;8(7):817–832.
 39. Yoshino T, et al. YM-58483, a selective CRAC 
channel inhibitor, prevents antigen-induced 
airway eosinophilia and late phase asthmatic 
responses via Th2 cytokine inhibition in animal 
models. Eur J Pharmacol. 2007;560(2-3):225–233.
 40. Korrapati MC, Shaner BE, Schnellmann RG. 
Recovery from glycerol-induced acute kidney 
injury is accelerated by suramin. J Pharmacol Exp 
Ther. 2012;341(1):126–136.
 41. Basile DP, Leonard EC, Tonade D, Friedrich JL, 
Goenka S. Distinct effects on long-term function 
of injured and contralateral kidneys following 
unilateral renal ischemia-reperfusion. Am J  
Physiol Renal Physiol. 2012;302(5):F625–F635.
 42. KDIGO Work Group. KDIGO clinical practice 
guideline for acute kidney injury. Kidney Int 
Suppl. 2012;17(1):1–138.
 43. Basile DP, Donohoe D, Roethe K, Osborn JL. 
Renal ischemic injury results in permanent 
damage to peritubular capillaries and influences 
long-term function. Am J Physiol Renal Physiol. 
2001;281(5):F887–F899.
 44. Badin JK, Bruning RS, Sturek M. Effect of met-
abolic syndrome and aging on Ca2+ dysfunction 
in coronary smooth muscle and coronary artery 
disease severity in Ossabaw miniature swine. Exp 
Gerontol. 2018;108:247–255.
